Amphastar Pharmaceuticals Inc (OQ:AMPH)

Mar 06, 2024 04:05 pm ET
Amphastar Pharmaceuticals to Present at the Barclays 26th Annual Global Healthcare Conference
RANCHO CUCAMONGA, CA / ACCESSWIRE / March 6, 2024 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO and Tony Marrs, EVP of Regulatory Affairs and Clinical Operations, will be presenting at the Barclays 26th Annual Global Healthcare Conference on Wednesday, March 13th, 2024 at 11:15 am EST. For access, visit Amphastar's Pharmaceuticals website at http://ir.amphastar.com. This webcast will be available for 30 days following the presentation.
Feb 28, 2024 04:05 pm ET
Amphastar Pharmaceuticals Reports Financial Results for the Three Months and Full-Year Ended December 31, 2023
Reports Net Revenues of $178.1 Million for the Three Months Ended December 31, 2023
Feb 20, 2024 04:01 pm ET
Amphastar Pharmaceuticals to Release Fourth Quarter Earnings and Hold Conference Call on February 28, 2024
RANCHO CUCAMONGA, CA / ACCESSWIRE / February 20, 2024 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the Company will release results for its fourth quarter of 2023 ended December 31, 2023, after the market closes on Wednesday, February 28, 2024, and will hold a conference call to discuss its financial results at 2:00 p.m. Pacific Time.
Jan 02, 2024 06:00 am ET
Amphastar Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference
RANCHO CUCAMONGA, CA / ACCESSWIRE / January 2, 2024 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Dr. Jack Zhang, CEO and President, and Bill Peters, CFO will be presenting at the 42nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2024 at 9:00 am PST. For access, visit Amphastar's Pharmaceuticals website at http://ir.amphastar.com. This webcast will be available for 30 days following the presentation.
Nov 20, 2023 04:20 pm ET
Amphastar Pharmaceuticals to Present at the Piper Sandler 35th Annual Healthcare Conference
RANCHO CUCAMONGA, CA / ACCESSWIRE / November 20, 2023 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO and Dan Dischner, S.V.P. of Corporate Communications, will participate in an Analyst-Moderated fireside chat at the Piper Sandler 35th Annual Healthcare Conference on Wednesday, November 29, 2023 at 9:30 am EST. For access, visit Amphastar's Pharmaceuticals website at http://ir.amphastar.com . This webcast will be available for 90 days following the presentation.
Nov 09, 2023 04:05 pm ET
Amphastar Pharmaceuticals to Present at the Jefferies London Healthcare Conference
RANCHO CUCAMONGA, CA / ACCESSWIRE / November 9, 2023 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO and Jacob Liawatidewi EVP of Corp. Administration, will participate in an Analyst-Moderated fireside chat at the Jefferies London Healthcare Conference on Wednesday, November 15, 2023 at 2:30 pm GMT. For access, visit Amphastar's Pharmaceuticals website at http://ir.amphastar.com . This webcast will be available for 90 days following the presentation.
Nov 08, 2023 04:05 pm ET
Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended September 30, 2023
Reports Net Revenues of $180.6 Million for the Three Months Ended September 30, 2023
Nov 01, 2023 04:05 pm ET
Amphastar Pharmaceuticals to Release Third Quarter Earnings and Hold Conference Call on November 8, 2023
RANCHO CUCAMONGA, CA / ACCESSWIRE / November 1, 2023 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the Company will release results for its third quarter of 2023 ended September 30, 2023, after the market closes on Wednesday, November 8, 2023, and will hold a conference call to discuss its financial results at 2:00 p.m. Pacific Time.
Sep 13, 2023 12:37 am ET
Amphastar Pharmaceuticals Announces Pricing of Offering of $300.0 Million of Convertible Senior Notes
RANCHO CUCAMONGA, CA / ACCESSWIRE / September 13, 2023 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) ("Amphastar") today announced the pricing of $300.0 million aggregate principal amount of 2.00% convertible senior notes due 2029 (the "notes") in a private placement to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"). Amphastar also granted the initial purchasers of the notes an option to purchase up to an additional $45.0 million aggregate
Sep 11, 2023 04:05 pm ET
Amphastar Pharmaceuticals Announces Proposed Private Offering of $300.0 Million of Convertible Senior Notes
RANCHO CUCAMONGA, CA / ACCESSWIRE / September 11, 2023 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) ("Amphastar") today announced that it intends to offer, subject to market conditions and other factors, $300.0 million aggregate principal amount of convertible senior notes due 2029 (the "notes") in a private placement to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"). Amphastar also intends to grant the initial purchasers of the notes an
Aug 31, 2023 04:05 pm ET
Amphastar Pharmaceuticals to Present at the Wells Fargo Healthcare Conference
RANCHO CUCAMONGA, CA / ACCESSWIRE / August 31, 2023 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO and Tony Marrs, EVP of Regulatory Affairs and Clinical Operations, will participate in an Analyst-Moderated fireside chat at the Wells Fargo Healthcare Conference on September 7, 2023 at 12:45 pm Eastern Time. For access, visit Amphastar's Pharmaceuticals website at http://ir.amphastar.com . This webcast will be available for 90 days following the presentation.
Aug 08, 2023 04:05 pm ET
Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended June 30, 2023
Reports Net Revenues of $145.7 Million for the Three Months Ended June 30, 2023
Aug 02, 2023 04:10 pm ET
Amphastar Pharmaceuticals to Release Second Quarter Earnings and Hold Conference Call on August 8, 2023
RANCHO CUCAMONGA, CA / ACCESSWIRE / August 2, 2023 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the Company will release results for its second quarter of 2023 ended June 30, 2023, after the market closes on Tuesday, August 8, 2023, and will hold a conference call to discuss its financial results at 2:00 p.m. Pacific Time.
Jun 30, 2023 04:05 pm ET
Amphastar Pharmaceuticals Completes Acquisition of BAQSIMI from Lilly
RANCHO CUCAMONGA, CA / ACCESSWIRE / June 30, 2023 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) ("Amphastar" or the "Company") today announced that it has completed the previously announced acquisition of BAQSIMI® from Eli Lilly and Company ("Lilly") (the "Acquisition").
May 31, 2023 04:15 pm ET
Amphastar Pharmaceuticals to Present at the Jefferies Healthcare Conference
RANCHO CUCAMONGA, CA / ACCESSWIRE / May 31, 2023 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO and Dan Dischner SVP of Corp. Communication, will participate in an Analyst-Moderated fireside chat at the Jefferies Healthcare Conference on June 8, 2023 at 2:30 pm Eastern Time. For access, visit Amphastar's Pharmaceuticals website at http://ir.amphastar.com . This webcast will be available for 90 days following the presentation.
May 09, 2023 04:05 pm ET
Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2023
Reports Net Revenues of $140.0 Million for the Three Months Ended March 31, 2023
May 03, 2023 04:30 pm ET
Amphastar Pharmaceuticals to Release First Quarter Earnings and Hold Conference Call on May 9, 2023
RANCHO CUCAMONGA, CA / ACCESSWIRE / May 3, 2023 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the Company will release results for its first quarter of 2023 ended March 31, 2023, after the market closes on Tuesday, May 9, 2023, and will hold a conference call to discuss its financial results at 2:00 p.m. Pacific Time.
Apr 24, 2023 06:45 am ET
Lilly to Divest BAQSIMI to Amphastar
Lilly focused on delivering the Company's unprecedented pipeline of next-generation medicines to help patients
Apr 24, 2023 06:45 am ET
Lilly to Divest BAQSIMI to Amphastar
Lilly focused on delivering the company's unprecedented pipeline of next-generation medicines to help patients
Apr 24, 2023 12:00 am ET
Amphastar Pharmaceuticals Business Update and Hold Conference Call on April 24th, 2023
RANCHO CUCAMONGA, CA / ACCESSWIRE / April 24, 2023 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the Company will provide a Business update and hold a Conference call today, Monday, April 24, 2023, at 6:00 am Pacific Time.
Apr 12, 2023 04:10 pm ET
Amphastar Pharmaceuticals to Present at the 22nd Annual Needham Virtual Healthcare Conference
RANCHO CUCAMONGA, CA / ACCESSWIRE / April 12, 2023 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO, Jacob Liawatidewi, EVP of Corporate Administration, Tony Marrs, EVP of Regulatory Affairs and Clinical Operations, and Dan Dischner SVP of Corp. Communication, will participate in an Analyst-Moderated fireside chat at the 22nd Annual Needham Virtual Healthcare Conference on April 19th, 2023 at 12:45 pm Eastern Time. For access, visit Amphastar's Pharmaceuticals website at http://ir.amphastar.co
Mar 08, 2023 06:00 am ET
Amphastar Pharmaceuticals Receives FDA Approval for Naloxone Hydrochloride Nasal Spray 4mg
RANCHO CUCAMONGA, CA / ACCESSWIRE / March 8, 2023 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) ("Amphastar" or the "Company") announced that the U.S. Food and Drug Administration ("FDA") has granted approval of its New Drug Application ("NDA") for naloxone hydrochloride nasal spray 4mg, which is delivered utilizing the Company's proprietary nasal delivery device. Naloxone hydrochloride nasal spray 4mg is indicated for the emergency treatment of known or suspected opioid overdose, as manifested by respiratory and/or central nervous sys
Feb 28, 2023 04:05 pm ET
Amphastar Pharmaceuticals Reports Financial Results for the Three Months and Full-Year Ended December 31, 2022
Reports Net Revenues of $135.0 Million for the Three Months Ended December 31, 2022
Feb 22, 2023 04:05 pm ET
Amphastar Pharmaceuticals to Release Fourth Quarter Earnings and Hold Conference Call on February 28, 2023
RANCHO CUCAMONGA, CA / ACCESSWIRE / February 22, 2023 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the Company will release results for its fourth quarter of 2022 ended December 31, 2022, after the market closes on Tuesday, February 28, 2023, and will hold a conference call to discuss its financial results at 2:00 p.m. Pacific Time.
Nov 22, 2022 06:00 am ET
Amphastar Pharmaceuticals to Present at the Piper Sandler 34th Annual Healthcare Conference
RANCHO CUCAMONGA, CA / ACCESSWIRE / November 22, 2022 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO and Tony Marrs, Sr. Vice President Regulatory Affairs and Clinical Operations, will participate in an Analyst-Moderated fireside chat at the Piper Sandler 34th Annual Healthcare Conference on November 30th, 2022 at 11:00 am Eastern Time. For access, visit Amphastar's Pharmaceuticals website at http://ir.amphastar.com. This webcast will be available for 90 days following the presentation.
Nov 10, 2022 04:05 pm ET
Amphastar Pharmaceuticals to Present at the 2022 Jefferies London Healthcare Conference
RANCHO CUCAMONGA, CA / ACCESSWIRE / November 10, 2022 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO and Jacob Liawatidewi, Executive V.P. of Corporate Administration Center, will participate in an Analyst-Moderated fireside chat at the 2022 Jefferies London Healthcare Conference on November 16th , 2022 at 3:50 pm Greenwich Mean Time. For access, visit Amphastar's Pharmaceuticals website at http://ir.amphastar.com . This webcast will be available for 90 days following the presentation.
Nov 07, 2022 04:05 pm ET
Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended September 30, 2022
Reports Net Revenues of $120.1 Million for the Three Months Ended September 30, 2022
Oct 28, 2022 06:00 am ET
Amphastar Pharmaceuticals to Release Third Quarter Earnings and Hold Conference Call on November 7, 2022
RANCHO CUCAMONGA, CA / ACCESSWIRE / October 28, 2022 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the Company will release results for its third quarter of 2022 ended September 30, 2022, after the market closes on Monday, November 7, 2022, and will hold a conference call to discuss its financial results at 2:00 p.m. Pacific Time.
Sep 02, 2022 06:00 am ET
Amphastar Pharmaceuticals to Present at the Wells Fargo 2022 Healthcare Conference
RANCHO CUCAMONGA, CA / ACCESSWIRE / September 2, 2022 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Jacob Liawatidewi, Executive V.P. of Corporate Administration Center and Sales and Marketing and Tony Marrs Sr. Vice President of Regulatory Affairs and Clinical Operations, will participate in an Analyst-Moderated fireside chat at the Wells Fargo 2022 Healthcare Conference on September 7th, 2022 at 1:20 pm Eastern Standard Time. For access, visit Amphastar's Pharmaceuticals website at http://ir.amphastar.com
Aug 16, 2022 06:00 am ET
Amphastar Pharmaceuticals Receives FDA Approval for Epinephrine Pre-Filled Syringes
RANCHO CUCAMONGA, CA / ACCESSWIRE / August 16, 2022 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the U.S. Food and Drug Administration ("FDA") has approved the Company's New Drug Application ("NDA") for Epinephrine injection USP, 1 mg/10mL (0.1 mg/mL) Single Dose Pre-Filled Syringe. Epinephrine injection is indicated to increase mean arterial blood pressure in adult patients with hypotension associated with septic shock. For the past 30 years, the Company has sold and marketed Epinephrine injection under the "grandfather" excepti
Aug 08, 2022 04:05 pm ET
Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended June 30, 2022
Reports Net Revenues of $123.5 Million for the Three Months Ended June 30, 2022
Aug 01, 2022 06:05 am ET
Amphastar Pharmaceuticals to Release Second Quarter Earnings and Hold Conference Call on August 8, 2022
RANCHO CUCAMONGA, CA / ACCESSWIRE / August 1, 2022 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the Company will release results for its second quarter of 2022 ended June 30, 2022, after the market closes on Monday, August 8, 2022, and will hold a conference call to discuss its financial results at 2:00 p.m. Pacific Time.
Jul 19, 2022 06:00 am ET
Amphastar Receives FDA Approval for Vasopressin
RANCHO CUCAMONGA, CA / ACCESSWIRE / July 19, 2022 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the U.S. Food and Drug Administration ("FDA") has approved the Company's Abbreviated New Drug Application ("ANDA") for Vasopressin injection, USP 20 Units/mL, 1mL Single Dose Vial. In December 2021, the Company had received FDA tentative approval for the ANDA. Vasopressin is indicated to increase blood pressure in adults with vasodilatory shock who remain hypotensive despite fluids and catecholamines. The FDA determined that Amphastar's vasopress
Jun 06, 2022 06:05 am ET
Amphastar Pharmaceuticals to Present at the Jefferies Healthcare Conference
RANCHO CUCAMONGA, CA / ACCESSWIRE / June 6, 2022 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, Executive V.P. and CFO, and Dan Dischner, V.P of Corporate Communications, will be presenting at the Jefferies Healthcare Conference on June 8, 2022 at 8:00 am Eastern Standard Time. For access, visit Amphastar's Pharmaceuticals website at http://ir.amphastar.com . This webcast will be available for 90 days following the presentation.
May 24, 2022 06:00 am ET
Amphastar Receives FDA Approval for Regadenoson
RANCHO CUCAMONGA, CA / ACCESSWIRE / May 24, 2022 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the U.S. Food and Drug Administration ("FDA") has approved the Company's Abbreviated New Drug Application ("ANDA") for Regadenoson injection, 0.08 mg/mL, 5mL Single Dose Pre-Filled Syringe. Regadenoson is indicated for radionuclide myocardial perfusion imaging (MPI) in patients unable to undergo adequate exercise stress. The FDA determined that Amphastar's regadenoson is bioequivalent and therapeutically equivalent to Astellas Pharma U.S., Inc's L
May 09, 2022 04:05 pm ET
Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2022
Reports Net Revenues of $120.4 Million for the Three Months Ended March 31, 2022
May 02, 2022 04:05 pm ET
Amphastar Pharmaceuticals to Release First Quarter Earnings and Hold Conference Call on May 9, 2022
RANCHO CUCAMONGA, CA / ACCESSWIRE / May 2, 2022 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the Company will release results for its first quarter of 2022 ended March 31, 2022, after the market closes on Monday, May 9th 2022, and will hold a conference call to discuss its financial results at 2:00 p.m. Pacific Time.
Apr 08, 2022 06:00 am ET
Amphastar Receives FDA Approval for Ganirelix Acetate Injection
RANCHO CUCAMONGA, CA / ACCESSWIRE / April 8, 2022 / Amphastar Pharmaceuticals, Inc., (NASDAQ:AMPH) announced that the U.S. Food and Drug Administration ("FDA") has approved the Company's Abbreviated New Drug Application ("ANDA") for Ganirelix Acetate Injection, 250mg/0.5mL in a prefilled syringe. Ganirelix acetate injection is indicated for the inhibition of premature luteinizing hormone (LH) surges in women undergoing controlled ovarian hyperstimulation. The FDA determined Amphastar's ganirelix is bioequivalent and therapeutically equivalent to Organon Pha
Apr 06, 2022 04:10 pm ET
Amphastar Pharmaceuticals to Present at the 21st Annual Needham Virtual Healthcare Conference
RANCHO CUCAMONGA, CA / ACCESSWIRE / April 6, 2022 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, Executive V.P. and CFO, Dan Dischner, V.P of Corporate Communications, Tony Marrs, Sr. V.P Regulatory Affairs and Clinical Operations, and Jacob Liawatidewi, Executive V.P. Corporate Administration Center and Sales & Marketing, will participate in an Analyst-Moderated fireside chat at the 21st Annual Needham Virtual Healthcare Conference on April 12, 2022 at 12:45 pm Eastern Standard Time. For access, visit Amphastar's Pharmaceutica
Mar 10, 2022 04:05 pm ET
Amphastar Pharmaceuticals Reports Financial Results for the Three Months and Full-Year Ended December 31, 2021
Reports Net Revenues of $120.9 Million for the Three Months Ended December 31, 2021
Mar 03, 2022 06:00 am ET
Amphastar Pharmaceuticals to Release Fourth Quarter Earnings and Hold Conference Call on March 10th, 2022
RANCHO CUCAMONGA, CA / ACCESSWIRE / March 3, 2022 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the Company will release results for its fourth quarter of 2021 ended December 31, 2021, after the market closes on Thursday, March 10th, 2022, and will hold a conference call to discuss its financial results at 2:00 p.m. Pacific Time.
Dec 29, 2021 06:00 am ET
Amphastar Receives FDA Tentative Approval for Vasopressin
RANCHO CUCAMONGA, CA / ACCESSWIRE / December 29, 2021 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the U.S. Food and Drug Administration ("FDA") has tentatively approved the Company's Abbreviated New Drug Application ("ANDA") for Vasopressin injection, USP 20 Units/mL, 1mL Single Dose Vial. Vasopressin is indicated to increase blood pressure in adults with vasodilatory shock who remain hypotensive despite fluids and catecholamines. The FDA determined that Amphastar's vasopressin is bioequivalent and therapeutically equivalent to Par Steril
Nov 22, 2021 06:00 am ET
Amphastar Pharmaceuticals to Present at the Piper Sandler 33rd Annual Virtual Healthcare Conference
RANCHO CUCAMONGA, CA / ACCESSWIRE / November 22, 2021 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, Executive V.P. and CFO, Dan Dischner, V.P of Corporate Communications, Tony Marrs, Sr. V.P Regulatory Affairs and Clinical Operations, and Jacob Liawatidewi, Executive V.P. Corporate Administration Center and Sales & Marketing, participated in an Analyst-Moderated fireside chat at the Piper Sandler 33rd Annual Virtual Healthcare Conference. This presentation will be made available November 22, 2021 at 10:00 am Eastern Standard T
Nov 11, 2021 04:05 pm ET
Amphastar Pharmaceuticals to Present at the Jefferies London Healthcare Conference
RANCHO CUCAMONGA, CA / ACCESSWIRE / November 11, 2021 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, Executive V.P. and CFO, Dan Dischner, V.P of Corporate Communications, Tony Marrs, Sr. V.P Regulatory Affairs and Clinical Operations, and Jacob Liawatidewi, Executive V.P. Corporate Administration Center and Sales & Marketing, will participate in an Analyst-Moderated fireside chat at the Jefferies London Healthcare Conference. This presentation will be pre-recorded and made available November 18, 2021 at 8:00 am GMT. For access, visit Amp
Nov 08, 2021 04:24 pm ET
Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended September 30, 2021
Reports Net Revenues of $112.2 Million for the Three Months Ended September 30, 2021
Oct 28, 2021 04:05 pm ET
Amphastar Pharmaceuticals to Release Third Quarter Earnings and Hold Conference Call on November 8th, 2021
RANCHO CUCAMONGA, CA / ACCESSWIRE / October 28, 2021 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the Company will release results for its third quarter of 2021 ended September 30, 2021, after the market closes on Monday, November 8, 2021, and will hold a conference call to discuss its financial results at 2:00 p.m. Pacific Time.
Sep 02, 2021 04:05 pm ET
Amphastar Pharmaceuticals to Present at the Wells Fargo 2021 Virtual Healthcare Conference
RANCHO CUCAMONGA, CA / ACCESSWIRE / September 2, 2021 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, Executive V.P. and CFO, Dan Dischner, V.P of Corporate Communications, Tony Marrs, Sr. V.P Regulatory Affairs and Clinical Operations, and Jacob Liawatidewi, Executive V.P. Corporate Administration Center and Sales & Marketing, will be presenting at the Wells Fargo 2021 Virtual Healthcare Conference on Thursday, September 9, 2021, at 2:00 pm Eastern time.
Aug 09, 2021 04:05 pm ET
Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended June 30, 2021
Reports Net Revenues of $101.7 Million for the Three Months Ended June 30, 2021
Jul 29, 2021 04:20 pm ET
Amphastar Pharmaceuticals to Release Second Quarter Earnings and Hold Conference Call on August 9th, 2021
RANCHO CUCAMONGA, CA / ACCESSWIRE / July 29, 2021 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the Company will release results for its second quarter of 2021 ended June 30, 2021, after the market closes on Monday, August 9th, 2021, and will hold a conference call to discuss its financial results at 2:00 p.m. Pacific Time.
Jun 15, 2021 04:05 pm ET
Amphastar Pharmaceuticals to Present at the Raymond James Human Health Innovation Conference
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced today that Bill Peters, Executive V.P. and CFO, Dan Dischner, V.P of Corporate Communications, Tony Marrs, Sr. V.P Regulatory Affairs and Clinical Operations, and Jacob Liawatidewi, Executive...
May 27, 2021 06:00 am ET
Amphastar Pharmaceuticals to Present at the Jefferies Virtual Healthcare Conference
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced today that Bill Peters, Executive V.P. and CFO, Dan Dischner, V.P of Corporate Communications, Tony Marrs, Sr. V.P Regulatory Affairs and Clinical Operations, and Jacob Liawatidewi, Executive...
May 07, 2021 04:05 pm ET
Amphastar Announces Buyback of 26% of the Equity in its ANP Subsidiary and Spin-off its Hanxin Subsidiary
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced the restructuring of its Chinese subsidiaries, primarily Amphastar Nanjing Pharmaceuticals Inc. (“ANP”). As part of the restructuring, Amphastar will buyback 26% of ANP’s equity currently...
May 06, 2021 04:05 pm ET
Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2021
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) (“Amphastar” or the “Company”) today reported results for the three months ended March 31, 2021. First Quarter Highlights Net revenues of $103.0 million for the first quarterGAAP net income of $5.0...
May 03, 2021 06:00 am ET
Amphastar Pharmaceuticals Receives FDA Approval for Morphine Sulfate Injection
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced that the U.S. Food and Drug Administration (“FDA”) approved the Company’s Abbreviated New Drug Application (“ANDA”) for Morphine Sulfate injection 1mg/mL in the 30mL Pump-Jet® Prefilled...
Apr 29, 2021 06:00 am ET
Amphastar Pharmaceuticals to Release First Quarter Earnings and Hold Conference Call on May 6th, 2021
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced that the Company will release results for its first quarter of 2021 ended March 31, 2021, after the market closes on Thursday, May 6th, 2021, and will hold a conference call to discuss its...
Apr 06, 2021 04:05 pm ET
Amphastar Pharmaceuticals to Present at the 20th Annual Needham Virtual Healthcare Conference
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced today that Bill Peters, CFO, Dan Dischner, V.P of Corporate Communications and HR, Tony Marrs, Sr. V.P Regulatory Affairs and Clinical Operations, and Jacob Liawatidewi, Executive V.P....
Mar 29, 2021 06:00 am ET
Amphastar Pharmaceuticals Receives FDA Approval for Dextrose Injection
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced that the U.S. Food and Drug Administration (“FDA”) approved the Company’s Abbreviated New Drug Application (“ANDA”) for Dextrose injection 50% in the 50 mL Luer-Jet® Prefilled Syringe System....
Mar 15, 2021 04:05 pm ET
Amphastar Pharmaceuticals Reports Financial Results for the Three Months and Full-Year Ended December 31, 2020
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) (“Amphastar” or the “Company”) today reported results for the three months and full-year ended December 31, 2020. Fourth Quarter Highlights Net revenues of $95.9 million for the fourth...
Mar 08, 2021 05:39 pm ET
Amphastar Pharmaceuticals to Release Fourth Quarter Earnings and Hold Conference Call on March 15th, 2021
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced that the Company will release results for its fourth quarter of 2020 ended December 31, 2020, after the market closes on Monday, March 15th, 2021, and will hold a conference call to discuss...
Feb 26, 2021 06:01 am ET
Amphastar Pharmaceuticals to Present at the Raymond James 2021 Institutional Healthcare Conference
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced today that Bill Peters, CFO, Dan Dischner, V.P of Corporate Communications and HR, Tony Marrs, Sr. V.P Regulatory Affairs and Clinical Operations, and Jacob Liawatidewi, Executive V.P....
Dec 29, 2020 06:00 am ET
Amphastar Announces Approval for Glucagon for Injection Kit, 1mg
Amphastar Pharmaceuticals, Inc., (NASDAQ: AMPH) announced that the U.S. Food and Drug Administration (“FDA”) has approved its Abbreviated New Drug Application (“ANDA”) for Glucagon for Injection Emergency Kit, 1 mg. Glucagon is indicated for the...
Nov 06, 2020 06:50 am ET
Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended September 30, 2020
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) (“Amphastar” or the “Company”) today reported results for the three months ended September 30, 2020. Third Quarter Highlights Net revenues of $83.4 million for the third quarterGAAP net income of...
Oct 29, 2020 04:05 pm ET
Amphastar Pharmaceuticals to Release Third Quarter Earnings and Hold Conference Call on November 6th, 2020
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced that the Company will release results for its third quarter of 2020 ended September 30, 2020, before the market opens on Friday, November 6th, 2020, and will hold a conference call to discuss...
Oct 06, 2020 06:00 am ET
Amphastar Pharmaceuticals Receives FDA Approval for Atropine Sulfate Injection
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced that the U.S. Food and Drug Administration (“FDA”) approved the Company’s Abbreviated New Drug Application (“ANDA”) for Atropine Sulfate injection 0.1mg/mL in the 10 mL Luer-Jet® Prefilled...
Sep 03, 2020 04:05 pm ET
Amphastar Pharmaceuticals to Present at the Wells Fargo 2020 Virtual Healthcare Conference
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced today that Bill Peters, CFO, Dan Dischner, Vice President of Corporate Communications and Human Resources, and Tony Marrs, Sr. Vice President Regulatory Affairs and Clinical Operations will...
Aug 06, 2020 04:05 pm ET
Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended June 30, 2020
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) (“Amphastar” or the “Company”) today reported results for the three months ended June 30, 2020. Second Quarter Highlights Net revenues of $85.8 million for the second quarterGAAP net loss of $0.2...
Jul 30, 2020 04:05 pm ET
Amphastar Pharmaceuticals to Release Second Quarter Earnings and Hold Conference Call on August 6th, 2020
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced that the Company will release results for its second quarter of 2020 ended June 30, 2020, after the market closes on Thursday, August 6th, 2020, and will hold a conference call to discuss its...
Jun 19, 2020 06:05 am ET
Amphastar Pharmaceuticals to Present at the BMO Prescriptions for Success Healthcare Conference
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced today that Bill Peters, CFO, Dan Dischner, Vice President of Corporate Communications and Human Resources, and Tony Marrs, Sr. Vice President Regulatory Affairs and Clinical Operations will...
Jun 12, 2020 06:30 am ET
Amphastar Pharmaceuticals to Present at the Raymond James Virtual 2020 Human Healthcare Innovation Conference
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced today that Bill Peters, CFO, Dan Dischner, Vice President of Corporate Communications and Human Resources, and Tony Marrs, Sr. Vice President Regulatory Affairs and Clinical Operations will...
Jun 09, 2020 06:00 am ET
Amphastar Pharmaceuticals, Inc. Receives FDA Approval for Succinylcholine Chloride Injection USP, 200 mg/10 mL (20 mg/mL) Multiple-Dose Vial
Amphastar® Pharmaceuticals, Inc., (NASDAQ: AMPH) (“Amphastar”), today announces that the U.S. Food and Drug Administration (“FDA”) has approved its Abbreviated New Drug Application (“ANDA”) for Succinylcholine Chloride Injection USP, 200 mg/10 mL...
Jun 02, 2020 04:05 pm ET
Amphastar Pharmaceuticals to Present at the Jefferies Virtual Healthcare Conference
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced today that Bill Peters, CFO and Dan Dischner, Vice President of Corporate Communications and Human Resources will be presenting at the Jefferies Virtual Healthcare Conference on Wednesday,...
May 07, 2020 04:05 pm ET
Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2020
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) (“Amphastar” or the “Company”) today reported results for the three months ended March 31, 2020. First Quarter Highlights Net revenues of $84.7 million for the first quarterGAAP net income of $3.9...
May 04, 2020 06:01 am ET
Amphastar Pharmaceuticals to Release First Quarter Earnings and Hold Conference Call on May 7th, 2020
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced that the Company will release results for its first quarter of 2020 ended March 31, 2020, after the market closes on Thursday, May 7th, 2020, and will hold a conference call to discuss its...
Apr 27, 2020 06:00 am ET
Amphastar Pharmaceuticals, Inc. Receives FDA Approval for Epinephrine Injection, USP 30mg/30mL (1mg/mL) Multiple Dose Vial
Amphastar Pharmaceuticals, Inc., (NASDAQ: AMPH) (“Amphastar”),  today announces that the U.S. Food and Drug Administration (“FDA”) has granted approval of its Abbreviated New Drug Application (“ANDA”) for Epinephrine Injection, USP 30mg/30mL...
Apr 13, 2020 05:16 pm ET
Amphastar Pharmaceuticals, Inc. Announces Simplification of Management Structure
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) (“Amphastar” or the “Company”), a California-based, specialty, generic pharmaceutical company, today announces a recent simplification of the Company’s management by removing a layer of management in...
Apr 09, 2020 06:01 am ET
Amphastar Pharmaceuticals to Present at the 19th Annual Needham Virtual Healthcare Conference
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced today that Jason Shandell, President and Bill Peters, CFO will be presenting at the 19th Annual Needham Virtual Healthcare Conference on Wednesday, April 15, 2020 at 12:50 p.m. Eastern Time....
Mar 12, 2020 04:05 pm ET
Amphastar Pharmaceuticals Reports Financial Results for the Three Months and Full Year Ended December 31, 2019
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) (“Amphastar” or the “Company”) today reported results for the three months and full year ended December 31, 2019. Fourth Quarter Highlights Net revenues of $83.4 million for the fourth...
Mar 05, 2020 04:05 pm ET
Amphastar Pharmaceuticals to Release Fourth Quarter Earnings and Hold Conference Call on March 12th, 2020
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced that the Company will release results for its fourth quarter of 2019 ended December 31, 2019, after the market closes on Thursday, March 12th, 2019, and will hold a conference call to discuss...
Feb 27, 2020 06:00 am ET
Amphastar Pharmaceuticals Receives FDA Approval for Supplement to its Abbreviated New Drug Application for Sodium Bicarbonate Injection, USP 8.4%, 50mEq/50mL
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced today that the U.S. Food and Drug Administration (“FDA”) granted approval of its supplemental Abbreviated New Drug Application for Sodium Bicarbonate Injection, USP, 8.4%, 50mEq/50mL...
Jan 28, 2020 04:05 pm ET
Amphastar Announces the Receipt of a MINOR CRL for Epinephrine Injection, USP 30mg/30mL (1mg/mL) Multiple Dose Vial
Amphastar Pharmaceuticals, Inc., (NASDAQ: AMPH) announced that on January 24, 2020, the U.S. Food and Drug Administration (“FDA”) issued a “MINOR” Complete Response Letter (“CRL”) for its Abbreviated New Drug Application (“ANDA”) for Epinephrine...
Nov 27, 2019 06:00 am ET
Amphastar Pharmaceuticals to Present at the 31st Annual Piper Jaffray Healthcare Conference
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced today that Jason Shandell, President and Bill Peters, CFO will be presenting at the 31st Annual Piper Jaffray Healthcare Conference on Wednesday, December 4, 2019 at 1:00 p.m. Eastern in New...
Nov 15, 2019 06:00 am ET
Amphastar Pharmaceuticals to Present at the Jefferies London Healthcare Conference
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced today that Jason Shandell, President will be presenting at the Jefferies London Healthcare Conference on Thursday, November 21, 2019 at 3:20 p.m. GMT in Aldwych, London, UK. This...
Nov 07, 2019 04:05 pm ET
Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended September 30, 2019
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) (“Amphastar” or the “Company”) today reported results for the three months ended September 30, 2019. Third Quarter Highlights Net revenues of $80.1 million for the third quarterGAAP net income of...
Nov 01, 2019 06:00 am ET
Amphastar Pharmaceuticals to Release Third Quarter Earnings and Hold Conference Call on November 7th, 2019
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced that the Company will release results for its third quarter of 2019 ended September 30th, 2019, after the market closes on Thursday, November 7th, 2019, and will hold a conference call to...
Aug 29, 2019 06:01 am ET
Amphastar Pharmaceuticals to Present at the Wells Fargo 2019 Healthcare Conference
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced today that Jason Shandell, President, and Bill Peters, CFO, will be presenting at the Wells Fargo 2019 Healthcare Conference on Thursday, September 5, 2019 at 3:05 p.m. Eastern Time, Boston,...
Aug 07, 2019 04:05 pm ET
Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended June 30, 2019
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) (“Amphastar” or the “Company”) today reported results for the three months ended June 30, 2019. Second Quarter Highlights Net revenues of $79.0 million for the second quarterGAAP net income of $47.8...
Aug 05, 2019 06:00 am ET
Amphastar Pharmaceuticals to Release Second Quarter Earnings and Hold Conference Call on August 7, 2019
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced that the Company will release results for its second quarter of 2019 ended June 30, 2019, after the market closes on Wednesday, August 7, 2019, and will hold a conference call to discuss its...
Jun 24, 2019 06:00 am ET
Amphastar Pharmaceuticals to Present at the BMO Prescriptions for Success Healthcare Conference
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced today that Jason Shandell, President, will be presenting at the BMO Prescriptions for Success Healthcare Conference on Tuesday, June 25, 2019 at 2:40 p.m. Eastern Time, New York, NY. This...
Jun 19, 2019 06:00 am ET
Amphastar Pharmaceuticals, Inc. Announces Settlement in Litigation with Momenta and Sandoz
Amphastar Pharmaceuticals, Inc., (NASDAQ: AMPH) today announced that it has entered into a settlement agreement (the “Settlement Agreement”) with Momenta Pharmaceuticals Inc. and Sandoz Inc., (collectively, “Momenta/Sandoz”). Under the terms of the...
Jun 14, 2019 06:00 am ET
Amphastar Pharmaceuticals to Present at the Raymond James Life Sciences and MedTech Healthcare Conference
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced today that Bill Peters, CFO, will be presenting at the Raymond James Life Sciences and MedTech Healthcare Conference on Wednesday, June 19, 2019 at 4:10 p.m. Eastern Time, New York, NY. This...
May 31, 2019 06:00 am ET
Amphastar Pharmaceuticals to Present at the Jefferies 2019 Healthcare Conference
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced today that Jason Shandell, President and Bill Peters, CFO, will be presenting at the Jefferies 2019 Healthcare Conference on Wednesday, June 5, 2019 at 8:30 a.m. Eastern Time, New York, NY....
May 10, 2019 06:00 am ET
Amphastar Pharmaceuticals to Present at the Bank of America Merrill Lynch Healthcare Conference 2019
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced today that Jason Shandell, President and Bill Peters, CFO, will be presenting at the Bank of America Merrill Lynch Healthcare Conference on Wednesday, May 15, 2019 at 3:40 p.m. Pacific Time,...
May 09, 2019 04:05 pm ET
Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2019
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) (“Amphastar” or the “Company”) today reported results for the three months ended March 31, 2019. First Quarter Highlights Net revenues of $79.8 million for the first quarterGAAP net income of...
May 06, 2019 06:00 am ET
Amphastar Pharmaceuticals to Release First Quarter Earnings and Hold Conference Call on May 9, 2019
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced that the Company will release results for its first quarter of 2019 ended March 31, 2019, after the market closes on Thursday, May 9, 2019, and will hold a conference call to discuss its...
Apr 16, 2019 07:45 am ET
Market Trends Toward New Normal in Cheniere Energy, CoreSite Realty, CalAmp, NextEra Energy Partners, LP, NewLink Genetics, and Amphastar Pharmaceuticals — Emerging Consolidated Expectations, Analyst
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Cheniere Energy, Inc. (NYSE:LNG), CoreSite Realty Corporation...
Mar 19, 2019 06:00 am ET
Amphastar Pharmaceuticals Receives FDA Approval for Enoxaparin Sodium Injection 300mg/3mL (100mg/mL) Multiple Dose Vial
Amphastar Pharmaceuticals, Inc., (NASDAQ: AMPH) announced that the U.S. Food and Drug Administration (FDA) granted approval of its Abbreviated New Drug Application (“ANDA”) for Enoxaparin Sodium Injection 300mg/3mL (100mg/mL) Multiple Dose Vial...
Mar 12, 2019 04:05 pm ET
Amphastar Pharmaceuticals Reports Financial Results for the Three Months and Full Year Ended December 31, 2018
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) (“Amphastar” or the “Company”) today reported results for the three months and full year ended December 31, 2018. Fourth Quarter Highlights Net revenues of $89.7 million for the fourth quarter, up...
Mar 07, 2019 04:01 pm ET
Amphastar Pharmaceuticals to Release Fourth Quarter Earnings and Hold Conference Call on March 12, 2019
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced that the Company will release results for its fourth quarter of 2018 ended December 31, 2018, after the market closes on Tuesday, March 12, 2019, and will hold a conference call to discuss...
Feb 26, 2019 08:15 am ET
Market Trends Toward New Normal in Micron Technology, Harris, Sientra, Noble, Amphastar Pharmaceuticals, and CECO Environmental — Emerging Consolidated Expectations, Analyst Ratings
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Micron Technology, Inc. (NASDAQ:MU), Harris Corporation (NYSE:HRS),...
Jan 03, 2019 06:00 am ET
Amphastar Pharmaceuticals, Inc. Announces Launch of Primatene® MIST to Nationwide Retail Pharmacies
Amphastar Pharmaceuticals, Inc., (NASDAQ: AMPH) announced today that Primatene® MIST has been launched. Primatene® MIST is an epinephrine inhalation aerosol bronchodilator suspension, which is the only FDA-approved metered dose inhaler (MDI) for...
Nov 27, 2018 08:45 am ET
New Research Coverage Highlights Phibro Animal Health, RadNet, Amphastar Pharmaceuticals, FibroGen, Sientra, and Flexion Therapeutics — Consolidated Revenues, Company Growth, and Expectations for 2018
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Phibro Animal Health Corporation (NASDAQ:PAHC), RadNet, Inc....
Nov 20, 2018 04:05 pm ET
Amphastar Pharmaceuticals to Present at the 30th Annual Piper Jaffray Healthcare Conference 2018
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced today that Bill Peters, CFO will be presenting at the 30th Annual Piper Jaffray Healthcare Conference on Wednesday, November 28, 2018 at 1:30 p.m. Eastern Time, New York, NY. This...
Nov 09, 2018 06:00 am ET
Amphastar Pharmaceuticals to Present at the Jefferies London Healthcare Conference 2018
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced today that Jason Shandell, President, and Bill Peters, CFO will be presenting at the Jefferies London Healthcare Conference on Wednesday, November 14, 2018 at 2:00 p.m. GMT in Aldwych,...
Nov 08, 2018 04:10 pm ET
Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended September 30, 2018
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) (“Amphastar” or the “Company”) today reported results for the three months ended September 30, 2018. Third Quarter Highlights Net revenues of $75.5 million for the third quarterGAAP net income...
Nov 07, 2018 09:55 pm ET
Amphastar Pharmaceuticals, Inc. Announces Reintroduction of Primatene® MIST
Amphastar Pharmaceuticals, Inc., (NASDAQ: AMPH) announced today that the U.S. Food and Drug Administration (FDA) granted approval of its New Drug Application (NDA) for Primatene® MIST (epinephrine inhalation aerosol bronchodilator suspension),...
Nov 06, 2018 04:05 pm ET
Amphastar Pharmaceuticals to Release Third Quarter Earnings and Hold Conference Call on November 8, 2018
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced that the Company will release results for its Third quarter of 2018 ended September 30, 2018, after the market closes on Thursday, November 8, 2018, and will hold a conference call to discuss...
Nov 02, 2018 04:05 pm ET
Amphastar Pharmaceuticals to Release Third Quarter Earnings and Hold Conference Call on November 8, 2018
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced that the Company will release results for its Third quarter of 2018 ended September 30, 2018, after the market closes on Wednesday, November 8, 2018, and will hold a conference call to...
Oct 16, 2018 09:15 am ET
Consolidated Research: 2018 Summary Expectations for Freightcar America, Star Bulk Carriers, Avis Budget Group, Adamas Pharmaceuticals, Model N, and Amphastar Pharmaceuticals — Fundamental Analysis, K
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Freightcar America, Inc. (NASDAQ:RAIL), Star Bulk Carriers Corp....
Aug 29, 2018 04:05 pm ET
Amphastar Pharmaceuticals to Present at the Wells Fargo Healthcare Conference 2018
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced today that Jason Shandell, President, and Bill Peters, CFO will be presenting at the Wells Fargo Healthcare Conference on Thursday, September 6, 2018 at 9:10 a.m. Eastern Time in Boston, MA....
Aug 20, 2018 08:00 am ET
Investor Expectations to Drive Momentum within Rapid7, 1-800 FLOWERS.COM, SMART Global, Prothena Corporation plc, Amphastar Pharmaceuticals, and Silvercorp Metals — Discovering Underlying Factors of I
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Rapid7, Inc. (NASDAQ:RPD), 1-800 FLOWERS.COM, Inc. (NASDAQ:FLWS), SMART...
Aug 08, 2018 04:05 pm ET
Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended June 30, 2018
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) (“Amphastar” or the “Company”) today reported results for the three months ended June 30, 2018. Second Quarter Highlights Net revenues of $71.0 million for the second quarterGAAP net loss of $2.8...
Aug 03, 2018 06:00 am ET
Amphastar Pharmaceuticals to Release Second Quarter Earnings and Hold Conference Call on August 8, 2018
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced that the Company will release results for its second quarter of 2018 ended June 30, 2018, after the market closes on Wednesday, August 8, 2018, and will hold a conference call to discuss its...
Jul 09, 2018 06:00 am ET
Amphastar Announces Expansion of Amphastar Nanjing Pharmaceuticals Inc.
Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced business expansion plans for its subsidiary, Amphastar Nanjing Pharmaceuticals Inc. (“ANP”). To date, ANP has provided Active Pharmaceutical Ingredients (“APIs”) and starting materials...
Jun 19, 2018 06:00 am ET
Amphastar Announces Approval for Isoproterenol Hydrochloride Injection, USP
Amphastar Pharmaceuticals, Inc., (NASDAQ:AMPH) announced that the U.S. Food and Drug Administration (“FDA”) has granted approval of its abbreviated new drug application (“ANDA”) for Isoproterenol Hydrochloride Injection, USP 0.2mg/mL, 1mL and...
Jun 05, 2018 08:00 am ET
Consolidated Research: 2018 Summary Expectations for Summit Therapeutics, Orbotech, Amphastar Pharmaceuticals, Mizuho Financial Group, Endo International plc, and AXT — Fundamental Analysis, Key Perfo
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Summit Therapeutics PLC (NASDAQ:SMMT), Orbotech, Ltd. (NASDAQ:ORBK),...
Jun 04, 2018 04:05 pm ET
Amphastar Pharmaceuticals to Present at the Jefferies Healthcare Conference 2018
Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO, will be presenting at the Jefferies Healthcare Conference on Tuesday, June 5, 2018 at 3:00 p.m. Eastern Time in New York, NY. This presentation will be made...
Jun 04, 2018 06:00 am ET
Amphastar Pharmaceuticals Receives FDA Approval for Semi-Purified Heparin at Amphastar Nanjing Pharmaceuticals
Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the U.S. Food and Drug Administration (“FDA”) granted approval of the company’s abbreviated new drug application (“ANDA”) supplement for the manufacture of semi-purified heparin at the...
May 14, 2018 06:00 am ET
Amphastar Pharmaceuticals Receives FDA Approval for Calcium Chloride Injection
Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the U.S. Food and Drug Administration (“FDA”) granted approval of the company’s abbreviated new drug application (“ANDA”) for Calcium Chloride injection 10% in the 10 mL Luer-Jet®...
May 10, 2018 06:00 am ET
Amphastar Pharmaceuticals to Present at the Bank of America Merrill Lynch Health Care Conference 2018
Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Jason Shandell, President, and Bill Peters, CFO, will be presenting at the Bank of America Merrill Lynch Health Care Conference on Tuesday, May 15, 2018 at 1:00 p.m. Pacific Time in...
May 09, 2018 04:05 pm ET
Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2018
Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) (“Amphastar” or the “Company”) today reported results for the three months ended March 31, 2018. First Quarter Highlights Net revenues of $58.4 million for the first quarterGAAP net loss of $7.2...
May 03, 2018 04:05 pm ET
Amphastar Pharmaceuticals to Release First Quarter Earnings and Hold Conference Call on May 9, 2018
Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the Company will release results for its first quarter of 2018 ended March 31, 2018, after the market closes on Wednesday, May 9, 2018, and will hold a conference call to discuss its...
Apr 12, 2018 08:30 am ET
Consolidated Research: 2018 Summary Expectations for Insight Enterprises, Amphastar Pharmaceuticals, EMC Insurance Group, Prothena Corporation plc, Mizuho Financial Group, and Baytex Energy — Fundamen
NEW YORK, April 12, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Insight Enterprises, Inc. (NASDAQ:NSIT), Amphastar Pharmaceuticals,...
Mar 26, 2018 06:00 am ET
Amphastar Pharmaceuticals to Present at the Needham’s 17th Annual Healthcare Conference
RANCHO CUCAMONGA, Calif., March 26, 2018 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO will be presenting at the Needham‘s 17th Annual Healthcare Conference on Wednesday, March 28, 2018 at 9:30 a.m. Eastern...
Mar 21, 2018 06:00 am ET
Amphastar Announces Final Judgment in the Patent Litigation against Momenta Pharmaceuticals, Inc. and Sandoz Inc.
RANCHO CUCAMONGA, Calif., March 21, 2018 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that on March 20, 2018, the United States Court for the District of Massachusetts (the “District Court”) entered final judgment in favor of Amphastar...
Mar 15, 2018 07:45 am ET
Market Trends Toward New Normal in Golden Ocean Group, Redhill Biopharma, Galapagos NV, Crawford, Amphastar Pharmaceuticals, and 51job — Emerging Consolidated Expectations, Analyst Ratings
NEW YORK, March 15, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Golden Ocean Group Limited (NASDAQ:GOGL), Redhill...
Mar 12, 2018 04:05 pm ET
Amphastar Pharmaceuticals Reports Financial Results for the Three Months and Fiscal Year Ended December 31, 2017
Reports Net Revenues of $60.4 Million for the Three Months Ended December 31, 2017
Mar 05, 2018 04:01 pm ET
Amphastar Pharmaceuticals to Release Fourth Quarter Earnings and Hold Conference Call on March 12, 2018
RANCHO CUCAMONGA, Calif., March 05, 2018 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the Company will release results for its fourth quarter of 2017 ended December 31, 2017, after the market closes on Monday, March 12,...
Dec 19, 2017 06:00 am ET
Amphastar Announces Approval for Sodium Nitroprusside Injection, USP
RANCHO CUCAMONGA, Calif., Dec. 19, 2017 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc., (NASDAQ: AMPH) announced that today the U.S. Food and Drug Administration (“FDA”) granted approval of its abbreviated new drug application (“ANDA”) for Sodium Nitroprusside Injection 25mg/mL,...
Nov 29, 2017 02:50 pm ET
Amphastar Announces Approval for Medroxyprogesterone Acetate Injectable Suspension, USP
RANCHO CUCAMONGA, Calif., Nov. 29, 2017 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc., (NASDAQ:AMPH) announced that today the U.S. Food and Drug Administration (“FDA”) granted approval of two abbreviated new drug applications (ANDAs) for Medroxyprogesterone Acetate Injectable Suspension, USP,...
Nov 20, 2017 06:00 am ET
Amphastar Pharmaceuticals to Present at the 29th Annual Piper Jaffray Healthcare Conference
RANCHO CUCAMONGA, Calif., Nov. 20, 2017 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Jason Shandell, President and Bill Peters, CFO will be presenting at the 29th Annual Piper Jaffray Healthcare Conference on Wednesday, November 29,...
Nov 08, 2017 04:05 pm ET
Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended September 30, 2017
RANCHO CUCAMONGA, Calif., Nov. 08, 2017 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) (“Amphastar” or the “Company”) today reported results for the three months ended September 30, 2017....
Nov 08, 2017 04:05 pm ET
Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended September 30, 2017
Reports Net Revenues of $57.9 Million for the Three Months Ended September 30, 2017
Sep 20, 2017 04:22 pm ET
Amphastar Pharmaceuticals Receives FDA Approval for Sodium Bicarbonate Injection
RANCHO CUCAMONGA, Calif., Sept. 20, 2017 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that on September 19, 2017, the U.S. Food and Drug Administration (“FDA”) granted approval of the company’s abbreviated new drug application (“ANDA”) for Sodium Bicarbonate injection 8.4% in the 50 mL Luer-Jet® Prefilled Syringe System. For the past 40 years, the company has sold and marketed the product under the “grandfather” exception to the FDA’s “Prescription Drug Wrap-Up” program.  Net revenues for the company’s sodium bicarbonate injection for the year ended December 31...
Aug 09, 2017 04:05 pm ET
Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended June 30, 2017
RANCHO CUCAMONGA, Calif., Aug. 09, 2017 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) (“Amphastar” or the “Company”) today reported results for the three months ended June 30, 2017....
Jun 01, 2017 04:05 pm ET
Amphastar Pharmaceuticals to Present at the Jefferies Global Healthcare Conference
RANCHO CUCAMONGA, Calif., June 01, 2017 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Jason Shandell, President, will be presenting at the Jefferies Global Healthcare Conference on Tuesday, June 6, 2017 at 10:00 a.m. Eastern Time in New York, NY....
May 08, 2017 04:05 pm ET
Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2017
RANCHO CUCAMONGA, Calif., May 08, 2017 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) (“Amphastar” or the “Company”) today reported results for the three months ended March 31, 2017....
May 04, 2017 12:13 pm ET
Amphastar Pharmaceuticals to Release First Quarter Earnings and Hold Conference Call on May 8, 2017
RANCHO CUCAMONGA, Calif., May 04, 2017 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the Company will release results for its first quarter of 2017 ended March 31, 2017, after the market closes on Monday, May 8th, 2017, and will hold a conference call to discuss its financial results at 2:00 p.m. Pacific Time....
Mar 13, 2017 04:21 pm ET
Amphastar Pharmaceuticals Reports Financial Results for the Three Months and Fiscal Year Ended December 31, 2016
RANCHO CUCAMONGA, Calif., March 13, 2017 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) (“Amphastar” or the “Company”) today reported results for the three months and fiscal year ended December 31, 2016....
Mar 09, 2017 04:01 pm ET
Amphastar Pharmaceuticals to Release Fourth Quarter Earnings and Hold Conference Call on March 13, 2017
RANCHO CUCAMONGA, Calif., March 09, 2017 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the Company will release results for its fourth quarter of 2016 ended December 31, 2016, after the market closes on Monday, March 13th, 2017, and will hold a conference call to discuss its financial results at 2:00 p.m. Pacific Time....
Dec 28, 2016 10:15 am ET
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Amphastar Pharmaceuticals, Inc. (AMPH)
NEW YORK, Dec. 28, 2016 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Amphastar Pharmaceuticals, Inc. ("Amphastar" or the "Company") (NASDAQ: AMPH). Such investors are advised to obtain additional information and assist the investigation by visiting the firm's site: www.bgandg.com/amph.
Dec 27, 2016 02:24 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Amphastar Pharmaceuticals, Inc. - AMPH
NEW YORK, Dec. 27, 2016 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Amphastar Pharmaceuticals, Inc. ("Abeona" or the "Company") (NASDAQ: AMPH).  Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 9980.
Nov 08, 2016 04:05 pm ET
Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended September 30, 2016
Reports Net Revenues of $64.2 Million for the Three Months Ended September 30, 2016...
Oct 28, 2016 06:00 am ET
Amphastar Pharmaceuticals to Release Third Quarter Earnings and Hold Conference Call on November 8, 2016
RANCHO CUCAMONGA, Calif., Oct. 28, 2016 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the Company will release results for its third quarter of 2016 ended September 30, 2016, after the market closes on Tuesday, November 8, 2016, and will hold a conference call to discuss its financial results at 2:00 p.m. Pacific Time....
Sep 19, 2016 06:52 pm ET
Cirrus Logic Set to Join the S&P MidCap 400; Amphastar Pharmaceuticals to Join S&P SmallCap 600
NEW YORK, Sept. 19, 2016 /PRNewswire/ -- S&P SmallCap 600 constituent Cirrus Logic Inc. (NASD: CRUS) will replace Fairchild Semiconductor International Inc. (NASD: FCS) in the S&P MidCap 400, and  Amphastar Pharmaceuticals Inc. (NASD: AMPH) will replace Cirrus Logic in the S&P SmallCap 600 after the close of trading on Wednesday, September 21. ON Semiconductor Corp. (NASD: ON) is acquiring Fairchild Semiconductor in a deal completed today.
Aug 08, 2016 04:05 pm ET
Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended June 30, 2016
RANCHO CUCAMONGA, Calif., Aug. 08, 2016 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) (“Amphastar” or the “Company”) today reported results for the three months ended June 30, 2016....
Aug 04, 2016 06:00 am ET
Amphastar Pharmaceuticals, Inc. Purchases International Medication Systems (UK) Limited from UCB PHARMA GmbH
RANCHO CUCAMONGA, Calif., Aug. 04, 2016 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) (“Amphastar” or the “Company”), announced today that, through its wholly owned UK subsidiary, Amphastar UK Limited, acquired a UK based corporation, International Medication Systems (UK) Limited, including its product trademarks, and other related product assets, as well as Marketing Authorizations for thirty-three products in the UK, Ireland, Australia, and New Zealand, representing eleven different injectable chemical entities, from UCB PHARMA GmbH for $7.7 million. The products are ...
Aug 01, 2016 06:00 am ET
Amphastar Pharmaceuticals to Release Second Quarter Earnings and Hold Conference Call on August 8, 2016
RANCHO CUCAMONGA, Calif., Aug. 01, 2016 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the Company will release results for its second quarter of 2016 ended June 30, 2016, after the market closes on Monday, August 8, 2016, and will hold a conference call to discuss its financial results at 2:00 p.m. Pacific Time....
Jun 03, 2016 06:00 am ET
Amphastar Pharmaceuticals to Present at the Jefferies 2016 Healthcare Conference
RANCHO CUCAMONGA, Calif., June 03, 2016 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Jason Shandell, President will be presenting at the Jefferies 2016 Healthcare Conference on Tuesday, June 7, 2016 at 2 p.m. Eastern Time in New York, NY....
May 09, 2016 04:05 pm ET
Amphastar Pharmaceuticals Reports Financial Results for the First Quarter Ended March 31, 2016
RANCHO CUCAMONGA, Calif., May 09, 2016 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) (“Amphastar” or the “Company”) today reported results for the first quarter ended March 31, 2016....
May 06, 2016 06:00 am ET
Amphastar Pharmaceuticals to Present at the 2016 Bank of America Merrill Lynch 19th Annual Health Care Conference
RANCHO CUCAMONGA, Calif., May 06, 2016 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Jason Shandell, President will be presenting at the Bank of America Merrill Lynch 19th Annual Health Care Conference on Thursday, May 12, 2016 at 9:20 a.m. Pacific Standard Time in Las Vegas, NV....

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.